U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214961) titled 'Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)' on July 21.
Brief Summary: This study is designed to investigate the safety, tolerability, and effectiveness of a new treatment called AB001 in both 177Lu-PSMA naive and 177Lu-PSMA experienced patients with advanced prostate cancer. AB001 targets a specific protein found on prostate cancer cells called prostate specific membrane antigen (PSMA) and delivers radioactive particles to kill the cancer cells.
The primary goal of the study is to determine the safety profile of AB001 and how well patients tolerate the treatmen...